Deutsche Bank
OVID icon

Deutsche Bank’s Ovid Therapeutics OVID Stock Holding History

Deutsche Bank’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105,177
Closed -$32.6K – 3698
2025
Q1 		$32.6K Hold
105,177
– – ﹤0.01% 3438
2024
Q4 		$97.8K Hold
105,177
– – ﹤0.01% 3288
2024
Q3 		$124K Hold
105,177
– – ﹤0.01% 3145
2024
Q2 		$81K Buy
105,177
+81,196
+339% +$226K ﹤0.01% 3181
2024
Q1 		$73.1K Buy
23,981
+1,097
+5% +$3.67K ﹤0.01% 3285
2023
Q4 		$73.7K Sell
22,884
-1,136
-5% -$3.88K ﹤0.01% 3346
2023
Q3 		$92.2K Buy
+24,020
New +$86.3K ﹤0.01% 3194
2021
Q3 		– Sell
-85,566
Closed -$335K – 4599
2021
Q2 		$335K Buy
85,566
+53,514
+167% +$211K ﹤0.01% 3478
2021
Q1 		$128K Sell
32,052
-440
-1% -$1.46K ﹤0.01% 3847
2020
Q4 		$75K Buy
32,492
+6,074
+23% +$28.3K ﹤0.01% 3993
2020
Q3 		$152K Buy
26,418
+4,633
+21% +$31K ﹤0.01% 3354
2020
Q2 		$160K Buy
+21,785
New +$102K ﹤0.01% 3235
2020
Q1 		– Sell
-23,165
Closed -$96K – 4681
2019
Q4 		$96K Buy
23,165
+12,896
+126% +$40.7K ﹤0.01% 3600
2019
Q3 		$33K Buy
10,269
+6,938
+208% +$15.8K ﹤0.01% 4122
2019
Q2 		$6K Sell
3,331
-253,931
-99% -$453K ﹤0.01% 5070
2019
Q1 		$454K Buy
257,262
+205,230
+394% +$513K ﹤0.01% 3511
2018
Q4 		$125K Sell
52,032
-196,420
-79% -$896K ﹤0.01% 4115
2018
Q3 		$1.41M Sell
248,452
-56,771
-19% -$430K ﹤0.01% 3083
2018
Q2 		$2.38M Buy
305,223
+9,501
+3% +$81.6K ﹤0.01% 2838
2018
Q1 		$2.09M Buy
295,722
+84,621
+40% +$685K ﹤0.01% 2830
2017
Q4 		$2.08M Buy
211,101
+6,607
+3% +$60.7K ﹤0.01% 2692
2017
Q3 		$1.75M Sell
204,494
-1,332
-0.6% -$11.1K ﹤0.01% 2629
2017
Q2 		$2.16M Buy
+205,826
New +$2.69M ﹤0.01% 2511

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Deutsche Bank's OVID Position: Q2 2025 in Review

Deutsche Bank sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 105,177 shares — an estimated $32.6K sold.

Deutsche Bank first reported a position in OVID in Q2 2017 and held it in 23 quarters. The position peaked at $2.38M in Q2 2018. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • Deutsche Bank reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 105,177 Ovid Therapeutics shares in Q2 2025, an estimated $32.6K.
  • Deutsche Bank first reported a position in Ovid Therapeutics in Q2 2017 and held it in 23 quarters.
  • Deutsche Bank's Ovid Therapeutics position peaked at $2.38M in Q2 2018.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.